Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adiponectin analogue - Allysta Pharmaceuticals

Next Previous
Drug Profile

Adiponectin analogue - Allysta Pharmaceuticals

Alternative Names: Adiponectin peptide analog - Allysta Pharmaceuticals; ADP 355; ALY 688; ALY 732; ALY-688-SR

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allysta Pharmaceuticals
  • Class Anti-inflammatories; Eye disorder therapies; Hepatoprotectants; Peptides
  • Mechanism of Action Adiponectin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Dry eyes
  • No development reported Non-alcoholic steatohepatitis

Most Recent Events

  • 28 May 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in Australia (SC, Injection)
  • 29 Mar 2023 Allysta Pharmaceutical completes a phase-II/III clinical trials in Dry eyes in USA (Ophthalmic) (NCT04899518)
  • 30 Aug 2021 Allysta Pharmaceutical terminates a phase I trial in Non-alcoholic steatohepatitis (In volunteers) in Australia (SC) because inability to recruit due to COVID-19 pandemic restrictions (NCT04855565)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top